FDA removed 12 peptides from Category 2: what changed
Published October 26, 2026. News from April 15, 2026, as summarized by the law firm Holland & Knight on October 16, 2026, cited below.
Quick take: a headline move on April 15 did not make any peptide legal to compound, according to Holland & Knight. The panel votes were advisory and the process is not finished.
Timeline per the law firm
| Date | Step | Status |
|---|---|---|
| Apr 15, 2026 | FDA removed 12 peptides from Category 2 | Final, but no peptide became eligible for compounding |
| Jul 23-24, 2026 | Advisory committee recommended six peptides for the 503A Bulks List | Advisory only |
| Oct 14, 2026 | Interim access policy sent to OMB | Not issued yet |
| By Feb 2027 | Second advisory meeting expected | No date set |
What is still missing
- No proposed or final FDA rule on peptide access exists, per the alert.
- FDA must decide whether to accept the panel's recommendations, then complete rulemaking.
- Any interim access would likely come with conditions, but those are not adopted requirements.
Canada is separate: see Health Canada vs FDA and the policy reversal explained.
Reality check: this summarizes a law firm's reading and can change. Not legal advice. US steps do not change Canadian rules.
Ready to order?
MOVRA10
Copy code and open Growth Guys
Paste it in the Promo code box in the order summary at checkout, then press Apply. Confirm the discount line before you pay.
Common questions
Did the April 15 change make peptides legal to compound?
Holland & Knight says it did not make any peptide eligible.
Is the panel vote binding?
No. It is advisory.
Does this apply in Canada?
No. Canadian rules are set by Health Canada.
Sources
- Holland & Knight: Peptides at a Crossroads, what wellness providers need to know (Oct 16, 2026)
- AJMC: 5 things to know about the FDA's peptide reversal (Aug 21, 2026)
Summarised in my own words. Read the originals for the full detail.